Abstract
Morphine 6-glucuronide (M6G) is an active metabolite of morphine that could be used as a drug, but its hydrolysis into morphine remains controversial. We investigated the acidic hydrolysis of M6G and found that the recovery of morphine did not exceed 5%. The stability of M6G was studied in different physiological compartments of male Sprague-Dawley rats. The formation of morphine after M6G incubation in feces was under 2% in the small intestine, whereas the formation of morphine in colon feces represented 85.6 ± 12.9% of the initial concentration of M6G. The stability of M6G was also determined ex vivo using the isolated perfused rat liver. The hepatic extraction ratio of M6G was very low (0.04 ± 0.02), but 88.7 ± 11.2% of the dose was excreted in bile. The elimination half-life of M6G in the perfusate (66.4 ± 20.6 min) was higher than the elimination half-life in bile (18.6 ± 2.5 min). The hydrolysis of M6G was low, with only 7.7% and 0.03% of morphine in the perfusate and bile, respectively. The perfusate level of morphine 3-glucuronide (M3G) resulting from morphine conjugation was 4.9 ± 3.6%. Anin vivo experiment demonstrated that after oral administration, M6G was absorbed per se in the proximal intestine, and the process was prolonged over the 24-hr experiment due to its reabsorption following enterohepatic recirculation. Finally, 10.5 ± 4.3% of morphine and 12.9 ± 5.1% of M3G compared with M6G AUCs were found in plasma. These results show that M6G is weakly converted into morphine when orally absorbed, with a kinetic profile similar to a slow release formulation.
Footnotes
-
Send reprint requests to: Pierre Sandouk, Hôpital Fernand Widal, INSERM U26, 200, rue du Faubourg Saint-Denis, 75475 Paris Cedex 10, France.
- Abbreviations used are::
- M6G
- morphine 6-glucuronide
- M3G
- morphine 3-glucuronide
- EHR
- enterohepatic recirculation
- IPRL
- isolated perfused rat liver
- AUC
- area under curve
- Received March 19, 1997.
- Accepted February 3, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|